热门资讯> 正文
Theravance面临多起试图阻止Zymeworks收购的诉讼
2026-09-10 23:03
- Theravance Biopharma (TBPH) is facing at least three lawsuits that aim to scuttle its planned $929M acquisition by Zymeworks (ZYME).
- The legal actions seek to enjoin Theravance from proceeding with the deal unless the company discloses material information allegedly withheld from proxy statements.
- The plaintiffs also call for the cancellation of the agreement and/or damages if the transaction goes through.
- Theravance also disclosed in the 8-K filing that it has received 13 demand letters from law firms representing shareholders regarding the deal.
More on Theravance Biopharma
- Theravance downgraded at Jones on Zymeworks acquisition
- Zymeworks to pay $17/share for Theravance Biopharma in $929M deal
- Seeking Alpha’s Quant Rating on Theravance Biopharma
- Historical earnings data for Theravance Biopharma
- Financial information for Theravance Biopharma
推荐文章
10月9日外盘头条：特朗普称中期选举前不会攻击伊朗 苹果将举行智能家居新品发布会 OpenAI年化营收500亿美元
英伟达、甲骨文、CoreWeave及其他AI股票因OpenAI营收报告下跌
美股前瞻 | 特朗普威胁中期选举前再袭伊！国际油价大升4%，三大期指齐跌；投行喊出美光3000美元目标价；华尔街知名多头公布五大首选股
资金复盘 | 北水加仓腾讯逾24亿港元！友邦保险、小米集团-W同获抢筹
华盛早报 | 美联储纪要偏鹰！年内或再加息一次；段永平"卖put"逆势布局腾讯；恒科成分股将扩容至50只
受惠AI热潮，三星电子Q3营业利润首次突破100万亿韩元，暴增近8倍；销售额为195.00万亿韩元
美联储纪要披露：7月联合干预支撑日元系财政部行动 未动用央行资金
SpaceX拟举债400亿美元采购英伟达芯片，其股价应声下跌
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
